209 related articles for article (PubMed ID: 31068386)
1. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
2. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
3. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
4. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling.
Ito T
Pathol Int; 2024 May; 74(5):239-251. PubMed ID: 38607250
[TBL] [Abstract][Full Text] [Related]
6. CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.
Fu M; Feng C; Wang J; Guo C; Wang Y; Gao R; Wang J; Zhu Q; Zhang X; Qi J; Zhang Y; Bian Y; Wang Z; Fang Y; Cao L; Hong B; Wang H
Clin Exp Med; 2024 May; 24(1):99. PubMed ID: 38748269
[TBL] [Abstract][Full Text] [Related]
7. Achaete-scute complex homolog-1 promotes DNA repair in the lung carcinogenesis through matrix metalloproteinase-7 and O(6)-methylguanine-DNA methyltransferase.
Wang XY; Jensen-Taubman SM; Keefe KM; Yang D; Linnoila RI
PLoS One; 2012; 7(12):e52832. PubMed ID: 23300791
[TBL] [Abstract][Full Text] [Related]
8. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
9. Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer.
Stinchcombe TE
Oncologist; 2017 Dec; 22(12):1510-1517. PubMed ID: 28778960
[TBL] [Abstract][Full Text] [Related]
10. Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.
Vitorino P; Chuang CH; Iannello A; Zhao X; Anderson W; Ferrando R; Zhang Z; Madhavan S; Karsunky H; Saunders LR
Transl Oncol; 2021 Jan; 14(1):100883. PubMed ID: 33074129
[TBL] [Abstract][Full Text] [Related]
11. Distinct regulation of ASCL1 by the cell cycle and chemotherapy in small cell lung cancer.
Liu Y; Wu Q; Jiang B; Hou T; Wu C; Wu M; Song H
Mol Cancer Res; 2024 Mar; ():. PubMed ID: 38512021
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction.
Domvri K; Yaremenko AV; Apostolopoulos A; Petanidis S; Karachrysafi S; Pastelli N; Papamitsou T; Papaemmanouil S; Lampaki S; Porpodis K
Heliyon; 2024 Mar; 10(5):e27208. PubMed ID: 38468968
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
Shijubou N; Sumi T; Kubo T; Sasaki K; Tsukahara T; Kanaseki T; Murata K; Keira Y; Terai K; Ikeda T; Yamada Y; Chiba H; Hirohashi Y; Torigoe T
J Cancer Res Clin Oncol; 2024 Mar; 150(3):125. PubMed ID: 38483588
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK
Future Oncol; 2022 Aug; 18(24):2639-2649. PubMed ID: 35815644
[TBL] [Abstract][Full Text] [Related]
16. ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers.
Martin-Vega A; Earnest S; Augustyn A; Wichaidit C; Gazdar A; Girard L; Peyton M; Kollipara RK; Minna JD; Johnson JE; Cobb MH
bioRxiv; 2023 Jun; ():. PubMed ID: 37398419
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Zhang Y; Tacheva-Grigorova SK; Sutton J; Melton Z; Mak YSL; Lay C; Smith BA; Sai T; Van Blarcom T; Sasu BJ; Panowski SH
Clin Cancer Res; 2023 Mar; 29(5):971-985. PubMed ID: 36692420
[TBL] [Abstract][Full Text] [Related]
18. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
20. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
